JRJuan Carlos Rodríguez-Aldama

Juan Carlos Rodríguez-Aldama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juan Carlos Rodríguez-Aldama has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Aging Mexican Women Living with HIV: Responding to Structural Oppression through Agency and Care Practices

    by Marla Naiví Toiber-Rodríguez, Teresita de Jesús Cabrera-López, Edgar Pérez-Barragán, Juan Carlos Rodríguez-Aldama, Xolyanetzin Montero-Pardo

    Introduction. Aging Mexican women living with HIV (AMWLWH) experience intersecting inequities associated with gender, age, socioeconomic status, and in some cases, Indigenous origin, shaping their access to HIV care. Objective: Analyze how AMWLWH respond to these conditions of structural oppression through agency and care practices. Method. Qualitative study conducted at a public HIV clinic in Mexico City (July 2024-March 2025). Twenty-seven cisgender AMWLWH aged ≥ 50 participated in semi-structured, face-to-face, Spanish-language interviews. Data were analyzed using reflexive thematic analysis and interpreted through an intersectional lens. Results. AMWLWH responded to structural oppression by continuing to engage in precarious work, protecting the continuity of HIV care, practicing self- and collective care, sharing situated knowledge, re-signifying aging, and imagining preferred futures centered on autonomy and dignity. Discussion and conclusion. AMWLWH actively negotiate structural constraints through self- and collective-care practices, economic strategies, and re-authoring later-life identities. Interventions and policies designed to enhance women’s agency, address age- and gender-related barriers, and support community-based care are essential to improving later-life wellbeing among AMWLWH.


  • Open Access

    Penicillin or Ceftriaxone for Neurosyphilis in People With HIV: A Retrospective, Propensity Score–Matched Multicenter Study in Mexico

    by Rodrigo Ville Benavides, Héctor Rivera-Villegas, Obed Ocampo-Valdez, Rafael Franco-Cendejas, Jaime Federico Andrade-Villanueva, Luz Alicia González-Hernández, Pedro Martínez-Ayala, Andrea Cárdenas-Ortega, Paulina Carreño-Pérez, Jezer Lezama-Mora, et al.

    Background: Neurosyphilis, ocular syphilis, and otosyphilis occur more frequently among people with HIV-1 and are associated with higher morbidity and treatment failure. Intravenous penicillin G remains the standard therapy but requires hospitalization or prolonged intravenous access, creating barriers that are amplified in resource-limited settings facing recurrent penicillin shortages. Ceftriaxone is a potential alternative; however, comparative data in people with HIV are limited. Methods: We conducted a multicenter retrospective cohort study of adults with HIV at 5 public hospitals and 2 outpatient HIV clinics in Mexico (2015–2024). Participants had confirmed neurosyphilis, ocular syphilis, or otosyphilis. Participants received intravenous penicillin G (18–24 million IU/day) or ceftriaxone (1–2 g/day) for 10–14 days. The primary outcome was early serological response (ESR), defined as a ≥4-fold nontreponemal titer decline or seroreversion at 6 months. We performed 1:1 propensity score matching (39 pairs, n = 78), followed by logistic regression in the matched cohort. Results: Of 143 participants, 104 (73%) received intravenous penicillin G and 39 (27%) ceftriaxone. In the matched cohort, ESR occurred in 74.4% of penicillin-treated participants and 71.8% of ceftriaxone-treated participants (odds ratio 0.88, 95% confidence interval .32–2.40; P = .80). The results were consistent across all prespecified sensitivity analyses. Conclusions: In this multicenter cohort of people with HIV diagnosed with neurosyphilis, ocular syphilis, or otosyphilis, ceftriaxone showed comparable ESR to intravenous penicillin G. These findings support ceftriaxone as a reasonable alternative when standard therapy is limited by penicillin shortages, limited inpatient capacity, or financial constraints.

  • Open Access

    Immune Reconstitution Inflammatory Syndrome Related to Antiretroviral Therapy Initiation in People With HIV and Mpox: An Observational Retrospective Study

    by Juan Carlos Rodríguez-Aldama, Edgar Pérez-Barragán, Graciela Hernández-Silva, Jezer Ivan Lezama-Mora, Ana Karen Olin-López, Berenice González-Flores, Raul Adrián Cruz-Flores, Brenda Crabtree-Ramírez

    The study aims to compare the outcomes of initiating antiretroviral therapy early vs late in people with HIV and mpox. No worse outcomes were found associated with mpox-related immune reconstitution inflammatory syndrome among those who started antiretroviral treatment early, suggesting initiation as soon as possible.


  • Open Access

    Clinical characteristics and outcomes of people living with HIV and ocular syphilis during the COVID-19 health emergency

    by Edgar Pérez-Barragán, Juan Carlos Rodríguez-Aldama, Paulina Rodríguez-Badillo, Karyme Guadalupe Villegas-Moreno, Gabriel Ezequiel Galindo-Magaña, Berenice González-Flores, Andrea González-Rodríguez, Raul Adrián Cruz-Flores

    The global shift in healthcare during the COVID-19 pandemic led to challenges in the care of people living with HIV. We conducted a retrospective study that aimed to delineate sociodemographic, clinical characteristics and outcomes, of people living with HIV diagnosed with ocular syphilis. Fifty-three people living with HIV were identified with ocular syphilis. Thirty-eight (71.6%) presented ocular symptoms. Twenty-three (43.3%) underwent lumbar puncture, 5 (9.4%) were positive for neurosyphilis. Forty-seven (88.6%) received treatment, 32 (68%) received standard treatment with aqueous crystalline penicillin G, and 15 (31.9%) were treated with alternative regimens due to the impossibility of hospitalization. Six (11.3%) individuals were lost to follow-up and/or did not receive treatment. Eighteen (56.2%) out of 32 individuals in the aqueous crystalline penicillin G group experienced serological response, 5 (15.6%) experienced treatment failure, and 9 (28.1%) were lost to follow-up. In the alternative therapy group, 12 out of 15 individuals (80%) experienced serological response. One (6.7%) experienced treatment failure, and 2 (13.3%) were lost to follow-up. During the COVID-19 health emergency in Mexico, alternative treatments for ocular syphilis demonstrated favorable clinical outcomes amid challenges in accessing hospitalization.


  • Open Access

    Preventable Deaths among HIV-Positive Patients: A Real-Life Perspective from a Teaching Hospital in Northern Mexico

    by Andrea Ramirez Fontes, Juan Carlos Rodriguez Aldama, Luis Antonio Sanchez Lopez, Nuevo León Council Of State For Prevention And Control Of Hiv/Aids, Samantha Flores-Treviño, César Adan Almendarez-Sánchez, Adrian Camacho Ortiz

    IntroductionAntiretroviral therapy (ART) in patients infected with human immunodeficiency virus (HIV) are more effective and better tolerated and for this reason the gap between life expectancy of an HIV-seropositive individual and a seronegative one has been closing. This study was carried out to identify the main causes of death in in HIV-infected patients in a tertiary-care hospital as well as relevant sociodemographic and clinical factors that contribute to their prognosis. AimThe aim of the present study is to identify the main causes of death in HIV/AIDS patients as well as relevant sociodemographic and clinical factors that contribute to their prognosis. MethodsA retrospective cohort was conducted with confirmed HIV-infected adult patients who died between January 2010 and January 2017. Sociodemographic and clinical data were taken from their clinical records to carry out a statistical analysis on the mortality of these patients and the relevant factors that contributed.ResultsA total of 120 patients with in-hospital mortality and HIV diagnosis were included, of these, 55% were allocated to an AIDS defining event, 75.8% had an HIV diagnosis of less than 6 months from their death, 88.3% received HIV testing for suspicion or confirmation of an AIDS defining event, and 50% had two or more active AIDS defining events at admission.ConclusionA major public health concern is a late HIV/AIDS diagnosis, a situation that is occurring in Mexico. Despite universal access to antiretroviral treatment, the most common causes of mortality in HIV-positive patients are still AIDS defining events, mainly tuberculosis and other opportunistic infections that with a prompt diagnosis might have been prevented if these patients had initiated early antiretroviral therapy.

  • Open Access

    Increasing rates of Clostridium difficile infection in Mexican hospitals

    by Laura Palau Dávila, Elvira Garza-González, Patricia Rodríguez-Zulueta, Rayo Morfín-Otero, Eduardo Rodríguez-Noriega, Diana Vilar-Compte, Juan C. Rodríguez-Aldama, Adrián Camacho-Ortiz